A detailed history of Arlington Capital Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Arlington Capital Management, Inc. holds 1,506 shares of ABBV stock, worth $271,080. This represents 0.27% of its overall portfolio holdings.

Number of Shares
1,506
Previous 1,304 15.49%
Holding current value
$271,080
Previous $223,000 33.18%
% of portfolio
0.27%
Previous 0.21%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$163.84 - $199.33 $33,095 - $40,264
202 Added 15.49%
1,506 $297,000
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $29,719 - $34,705
-192 Reduced 12.83%
1,304 $223,000
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $64,121 - $72,216
-466 Reduced 23.75%
1,496 $231,000
Q3 2023

Oct 24, 2023

SELL
$133.59 - $154.65 $11,355 - $13,145
-85 Reduced 4.15%
1,962 $292,000
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $18,799 - $21,650
-130 Reduced 5.97%
2,047 $326,000
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $42,737 - $51,253
309 Added 16.54%
2,177 $352,000
Q3 2022

Oct 31, 2022

BUY
$134.21 - $153.93 $250,704 - $287,541
1,868 New
1,868 $251,000
Q2 2022

Aug 10, 2022

SELL
$137.62 - $174.96 $321,342 - $408,531
-2,335 Closed
0 $0
Q4 2021

Jan 31, 2022

BUY
$107.43 - $135.93 $250,849 - $317,396
2,335 New
2,335 $316,000
Q3 2021

Nov 03, 2021

SELL
$106.4 - $120.78 $261,424 - $296,756
-2,457 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $12,835 - $14,299
122 Added 5.22%
2,457 $277,000
Q1 2021

May 10, 2021

SELL
$102.3 - $112.62 $80,612 - $88,744
-788 Reduced 25.23%
2,335 $253,000
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $251,370 - $339,376
3,123 New
3,123 $335,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Arlington Capital Management, Inc. Portfolio

Follow Arlington Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arlington Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Arlington Capital Management, Inc. with notifications on news.